Agios Pharmaceuticals Inc (MEX:AGIO)
MXN 397.93 0 (0%) Market Cap: 47.15 Bil Enterprise Value: 37.43 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 36/100

Agios Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 15, 2023 / 03:00PM GMT
Release Date Price: MXN432.08
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning, everyone. Thanks for joining us. I am Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have the Agios team with us. So we have Brian Goff, CEO; as well as Sarah Gheuens, Chief Medical Officer.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Maybe to start here, Brian, you joined Agios as a CEO last year. And can you just discuss any notable changes in strategy in addition to where you stand on your lead (inaudible) commercial assets as well as the pipeline at this point?

Brian M. Goff
Agios Pharmaceuticals, Inc. - CEO & Director

Sure. Thanks a lot. First off, thanks so much for hosting us. We are thrilled to be here. We have a lot to talk about. It's a very exciting time for Agios. And the last year, for me personally and as well for Agios has been absolutely tremendous. We had many accomplishments, which we're very happy to talk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot